Theravance Biopharma TBPH Cash Flow Statement (2013-2026)

NASDAQ TBPH
$17.08 +0.00 (+0.00%)
As of: Sep 4, 2026 · 2:20 PM EDT
Reported Financials

Theravance Biopharma Quarterly Cash Flow Statement

Periods 54 quarters
Latest Jun 2026

Theravance Biopharma reported cash from operations of -$6.96M and free cash flow of -$6.96M for the quarter ended Jun 2026, down 103.3% year over year. This cash flow statement covers 54 quarters of results from Mar 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-35.31M-31.99M-24.67M-4.41M911.58M168.65M-21.69M-15.64M-8.95M-8.51M-11.66M-16.53M-12.70M-25.11M-13.58M54.84M3.62M49.51M-4.93M-5.90M
Share-based CompensationStock Comp.
14.37M16.92M14.54M9.71M8.53M6.95M7.02M6.26M6.26M5.82M5.23M5.38M4.96M5.83M4.88M4.54M1.98M4.48M5.82M5.99M
Deferred Taxes
-0.51M-0.56M0.09M-6.59M-1.85M-10.69M0.99M0.03M-3.00M-0.22M
Cash from Discontinued OperationsCash from Discont. Ops
2.82M0.61M-1.00M-5.21M-178.97M
Asset Writedowns and ImpairmentWritedown
1.56M
Cash from OperationsCash from Ops.
-70.55M-45.25M-26.68M-14.12M-22.14M-124.06M-11.22M-12.44M-2.49M-0.85M-1.02M-4.42M-5.20M-0.90M43.04M208.07M-6.51M-6.06M73.28M-6.96M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
1.01M1.03M0.34M0.97M0.97M1.71M1.03M0.79M0.91M1.43M1.10M1.13M1.13M1.05M0.97M0.94M1.00M1.11M1.06M1.08M
Depreciation & Amortization (CF)Dep. & Amort.
Change in Working Capital
Change in ReceivablesChange Receivables
Change in InventoryChange Inventory
Change in Account PayablesChange Payables
-1.82M-5.74M-1.62M1.59M2.18M-3.76M1.00M-0.92M0.27M-0.35M0.18M-0.00M-0.22M0.79M0.17M-0.73M0.54M0.35M-1.47M-0.45M
Change in Accured ExpensesChange Accured Exp.
-3.45M-0.65M-10.34M-0.79M-7.33M4.38M-4.34M-2.20M-0.12M-0.44M-3.40M1.14M0.73M2.99M-1.51M3.19M3.61M-1.27M-4.87M4.68M
Change in TaxesChange Taxes
-22.62M
Other Working Capital ChangesOther WC Changes
-2.80M-2.81M-0.01M-0.17M-0.01M-0.01M-0.01M-0.01M-0.01M-0.20M
Investing Activities
Capital ExpendituresCapex
1.04M0.44M0.25M0.11M-0.06M0.27M0.94M0.85M0.02M0.68M0.09M0.04M0.01M0.19M0.01M
Sales of Property, Plant and EquipmentPP&E (Sale)
1.85M0.02M0.21M1.30M
Divestments
Change in Acquisitions & DivestmentsChange Acquisitions
30.00M64.80M48.50M43.20M17.00M49.30M62.72M8.66M44.02M28.24M27.50M40.05M32.60M20.35M24.50M65.53M96.00M41.50M
Cash from Investing ActivitiesCash from Investing
-35.79M10.82M31.92M7.51M1,075.41M39.16M-43.05M11.05M-0.02M-0.68M17.03M-3.03M-17.40M15.69M30.63M-36.26M-100.25M0.59M52.59M-60.40M
Financing Activities
Other financing activitiesOther financing
0.60M-20.68M-0.00M0.17M0.13M0.49M0.24M1.14M
Cash from Financing ActivitiesCash from Financing
-2.29M0.15M-1.45M0.14M-722.03M-35.47M-56.24M-80.68M-31.40M-30.61M-1.72M-0.04M-0.37M-0.36M-0.85M-0.50M-0.40M-1.49M-5.58M-0.97M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
1.81M1.21M0.69M0.01M0.20M0.36M0.57M0.16M0.17M0.01M0.17M0.02M0.07M
Net Equity Issued and RepurchasedNet Equity Issued
0.03M0.03M0.02M
Additional items
Change in Cash
-83.53M-31.46M4.41M-7.08M331.25M-120.37M-110.51M-82.07M-33.91M-32.14M14.29M-7.49M-22.97M14.42M72.82M171.31M-107.15M-6.97M120.30M-68.33M
Free Cash FlowFCF
-71.59M-45.69M-26.93M-14.23M-22.08M-124.32M-12.16M-13.29M-2.51M-1.53M-1.11M-4.45M-5.21M-1.09M43.04M208.07M-6.51M-6.07M73.28M-6.96M
Net Cash FlowNCF
-108.63M-34.28M3.79M-6.46M331.25M-120.37M-110.51M-82.07M-33.91M-32.14M14.29M-7.49M-22.97M14.42M72.82M171.31M-107.15M-6.97M120.30M-68.33M